|Bid||0.0000 x 4000|
|Ask||0.0000 x 2900|
|Day's range||2.0650 - 2.2500|
|52-week range||2.0200 - 8.1300|
|Beta (5Y monthly)||0.77|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||7.75|
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process. The biotech's vaccine tablets could have a few advantages that Moderna's shots don't, including one in particular, that might be a public health holy grail at the moment. For Vaxart's stock to beat Moderna's next year, two things need to happen.
Vaxart (NASDAQ: VXRT) is working on a coronavirus vaccine candidate. Recently, Vaxart said its omicron-specific candidate and its original candidate both protected against the variant in preclinical tests. Of course, even if Vaxart is successful, the company will make it to market much later than bigger rivals.